Lucid Diagnostics (NASDAQ:LUCD) Posts Earnings Results, Misses Estimates By $0.06 EPS

Lucid Diagnostics (NASDAQ:LUCD) issued its earnings results on Monday. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.06), Zacks reports.

Lucid Diagnostics Trading Down 0.3 %

LUCD stock traded down $0.01 during mid-day trading on Monday, hitting $1.52. 451,854 shares of the company were exchanged, compared to its average volume of 353,014. Lucid Diagnostics has a twelve month low of $0.63 and a twelve month high of $1.63. The firm has a fifty day simple moving average of $1.20 and a 200 day simple moving average of $0.98. The company has a market capitalization of $89.90 million, a PE ratio of -1.32 and a beta of 1.34.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets lowered their price target on shares of Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a report on Monday, December 9th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $3.63.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.